Skip to content

Study · Observational study · n = 7,637 · 2019

3 results

Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10).

Brown-Frandsen K, Emerson SS, McGuire DK, Pieber TR, Poulter NR, Pratley RE, Zinman B, Ranthe MF, Grøn R, Lange M, Moses AC, Örsy P, Buse JB

Diabetes, obesity & metabolism1 Apr 2019Cited by 12 (Europe PMC)

PMID30793465 (opens in a new tab)PMCIDPMC6504564 (opens in a new tab)DOI10.1111/dom.13677 (opens in a new tab)PepBankPUB-30793465
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In people with type 2 diabetes at high cardiovascular risk on basal insulin, concomitant liraglutide use was associated with a lower hazard of MACE than no liraglutide use (HR 0.62).

    In plain wordsIn people with type 2 diabetes at high heart risk on basal insulin, using liraglutide was linked to fewer major heart events.

    Peptide
    Liraglutide
    Outcome
    DecreaseMajor adverse cardiovascular events (MACE)
    Study

    n = 7,637

    Comparator
    No liraglutide use
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · mean exposure 530.2 daysAs given in this study (human).

    Measurements

    Hazard ratio
    0.62 HR
    MACE, 95% CI 0.41-0.92

    Source sentences

    Summary
    Liraglutide use versus no liraglutide use was associated with significantly lower hazard rates for MACE [0.62 (0.41; 0.92)95%CI ] and all-cause mortality [0.50 (0.29; 0.88)95%CI ].
    3 context sentences
    Summary · context
    Patients with type 2 diabetes and high cardiovascular risk were randomized 1:1 to degludec or glargine U100.
    Summary · context
    Hazard ratios for MACE/mortality were calculated using a Cox regression model adjusted for treatment and time-varying liraglutide use at any time during the trial, without interaction.
    Summary · context
    At baseline, 436/7637 (5.7%) patients were treated with liraglutide; after baseline, 187/7637 (2.4%) started and 210/7637 (2.7%) stopped liraglutide.
  2. 02HumanObservational studyEfficacy outcome

    In people with type 2 diabetes at high cardiovascular risk on basal insulin, concomitant liraglutide use was associated with a lower hazard of all-cause death than no liraglutide use (HR 0.50).

    In plain wordsIn people with type 2 diabetes at high heart risk on basal insulin, using liraglutide was linked to fewer deaths from any cause.

    Peptide
    Liraglutide
    Outcome
    DecreaseAll-cause mortality
    Study

    n = 7,637

    Comparator
    No liraglutide use
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated · mean exposure 530.2 daysAs given in this study (human).

    Measurements

    Hazard ratio
    0.5 HR
    all-cause mortality, 95% CI 0.29-0.88

    Source sentences

    Summary
    Liraglutide use versus no liraglutide use was associated with significantly lower hazard rates for MACE [0.62 (0.41; 0.92)95%CI ] and all-cause mortality [0.50 (0.29; 0.88)95%CI ].
    3 context sentences
    Summary · context
    Patients with type 2 diabetes and high cardiovascular risk were randomized 1:1 to degludec or glargine U100.
    Summary · context
    Hazard ratios for MACE/mortality were calculated using a Cox regression model adjusted for treatment and time-varying liraglutide use at any time during the trial, without interaction.
    Summary · context
    At baseline, 436/7637 (5.7%) patients were treated with liraglutide; after baseline, 187/7637 (2.4%) started and 210/7637 (2.7%) stopped liraglutide.
  3. 03HumanObservational studySafety outcome

    In people with type 2 diabetes at high cardiovascular risk on basal insulin, the rate of severe hypoglycaemia did not differ significantly with versus without liraglutide use.

    In plain wordsIn people with type 2 diabetes at high heart risk on basal insulin, severe low blood sugar was not significantly different with or without liraglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeSevere hypoglycaemia rate
    Study

    n = 7,637

    Comparator
    No liraglutide use
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · mean exposure 530.2 daysAs given in this study (human).

    Source sentences

    Summary
    There was no significant difference in the rate of severe hypoglycaemia with versus without liraglutide use.
    3 context sentences
    Summary · context
    Patients with type 2 diabetes and high cardiovascular risk were randomized 1:1 to degludec or glargine U100.
    Summary · context
    Hazard ratios for MACE/mortality were calculated using a Cox regression model adjusted for treatment and time-varying liraglutide use at any time during the trial, without interaction.
    Summary · context
    At baseline, 436/7637 (5.7%) patients were treated with liraglutide; after baseline, 187/7637 (2.4%) started and 210/7637 (2.7%) stopped liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.